Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer

Blood

Volumn 88, Issue 4, 1996, Pages 1501-1508

  Eibl, Brigitte ^a   Schwaighofer, Hubert ^b   Nachbaur, David ^b   Marth, Christian ^b   Gächter, Anne ^b   Knapp, Rudolf ^b   Böck, Günther ^b   Gassner, Christoph ^b   Schiller, Lothar ^b   Petersen, Finn ^b   Niederwieser, Dietger ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; EPIRUBICIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

EID: 9444243905     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.4.1501.bloodjournal8841501     Document Type: Article

References (55)

1. Weiden PL, Flournoy N, Thomas ED, Prentice RL, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068, 1979
2. Butturini A, Bortin MM, Gale RP: Graft-vs-leukemia following bone marrow transplantation. Bone Marrow Transplant 2:233, 1987
3. Kolb H-J, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, De Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 5:2041, 1995
4. Barnes DWH, Loutit JF: Treatment of murine leukaemia with x-rays and homologous bone marrow. Br Med J 2:626, 1956
5. Truitt RL, Gale RP, Bortin MM: Cellular Immunotherapy of Cancer. New York, NY, Liss, 1987
6. Sosman JA, Sondel PM: The graft versus leukemia effect following bone marrow transplantation: A review of laboratory and clinical data. Hematol Rev 2:77, 1987
7. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey H, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
8. Jones RJ, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649, 1991
9. Mackinnon S, Hows JM, Goldman JM: Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 76:2037, 1990
10. Falkenburg JH, Goselink HM. van der Harst D, van Luxemburg-Heijs AP, Kooy-Winkelaar YM, Faber L, de Kroon J, Brand A, Fibbe WE, Willemze R, Goulmy E: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 174:27, 1991
11. Niederwieser D, Grassegger A. Auböck J, Herold M, Nachbaur D, Rosenmayr A, Gächter A, Nussbaumer W, Gaggl S, Ritter M, Huber Ch: Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 81:2200, 1993
12. Griem P, Wallny H-J, Falk K, Rötschke O, Arnold B, Schönrich G, Hämmerling G, Rammensee H-G: Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 65:633, 1991
13. Miconnet I, de La Salle V, Tucek C, Huchet R, Bonardelle D, Bruley-Rosset M: Tissue distribution and polymorphism of minor histocompatibility antigens involved in GVHR. Immunogenetics 39:178, 1994
14. Voogt PJ, Goulmy E, Veenhof WF, Hamilton M, Fibbe WE, Van Rood JJ, Falkenburg JH: Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. J Exp Med 168:2337, 1988
15. De Bueger M, Bakker A, Van Rood JJ, van der Woude F, Goulmy E: Tissue distribution of human minor histocompatibility antigens: Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 149:1788, 1992
16. Wallny HJ, Rammensee HG: Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 343:275, 1990
17. Loveland B, Wang C-R, Yonekawa H, Hermel E, Lindahl-Fischer K: Maternally transmitted histocompatibility antigen of mice: A hydrophobic peptide of a mitochondrially encoded protein. Cell 60:971, 1990
18. Perreault C, Decary F, Brochu S, Gyger M, Belanger R, Roy D: Minor histocompatibility antigens. Blood 76:1269, 1990
19. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ: The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44:959, 1986
20. Den Haan JMM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268:1476, 1995
21. Gratwohl A, Hermans J, Baldomero H: Hematopoietic precursor cell transplants in Europe: Activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 17:137, 1995
22. Soule HD, Vasquez J, Long A, Albert S, Brennan MB: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:1409, 1973
23. Whang-Peng J, Lee EC, Kao-Shan C-S, Seibert K, Lippman M: Cytogenetic studies of human breast cancer lines: MCF-7 and derived variant sublines. J Natl Cancer Inst 71:687, 1983
24. Judge SM, Chatterton RT Jr: Progesterone-specific stimulation of triglyceride biosynthesis in a breast cancer cell line (T-47D). Cancer Res 43:4407, 1983
25. Lasfargues EY, Cantinho WG, Moore IH: Heterotransplantation of a human breast carcinoma cell line. Cancer Res 32:2365, 1972
26. Lasfargues EY, Ozzello L: Cultivation of human breast carcinomas. J Natl Cancer Inst 21:1131, 1958
27. Marth C, Gastl G, Zech J, Zilla P, Mayer I, Fasol R, Huber C, Daxenbichler G: Characterization of an interferon-resistant mutant of the human breast cancer cell line BT-20. J Interferon Res 7:195, 1987
28. Engel LV, Young NA, Tralka TS, Lippman ME, O'Brian SJ, Joyce MJ: Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38:3352, 1978
29. Cailleau R, Young R, Olive M, Reeves WJ Jr: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53:661, 1974
30. Fogh J, Trempe G: New human tumor cell lines, in Fogh J (ed): Human Tumor Cells In Vitro. New York, NY, Plenum, 1975, 115
31. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215, 1988
32. Lempert M, Mytilineos J, Deufel A, Scherer S, Opelz G: HLA-A typing by the PCR-SSP method in 123 individuals carrying a serological blank. Tissue Antigens (submitted)
33. Bunce M, Fanning GC, Welsh KI: Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). Tissue Antigens 45:81, 1995
34. Olerup O, Zetterquist H: HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donorrecipient matching in cadaveric transplantation. Tissue Antigens 39:225, 1992
35. Zier K, Huber Ch, Braunsteiner H: Linear density gradient separation of human lymphocyte subsets. I. Analysis by mixed leukocyte culture and cell mediated lympholysis responses. Eur J Immunol 7:366, 1977
36. Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF: Monoclonal antibodies for analysis of the HLA system. Immunol Rev 47:3, 1979
37. Niederwieser D, Auböck J, Troppmair J, Herold M, Schuler G, Boeck G, Lotz J, Fritsch P, Huber C: IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol 140:2556, 1988
38. Speck B: Bone marrow transplantation in leukemia. Anticancer Res 1:249, 1981
39. Ritter M, Huber C, Auböck J, Pohl-Markl H, Troppmair J, Herold M, Gächter A, Schönitzer D, Böck G, Nachbaur D, Westhoff U, Eibl B, Schwaighofer H, Thaler J, Grosse-Wilde H, Niederwieser D: Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive MHC-class I antigen expression and cytokine-induced activation status. Immunology 81:569, 1994
40. Antman K, Corringham R, de Vries E, Elfenbein G, Gisselbrecht GC, Herzig R, Juttner C, Kaizer H, Kennedy J, Kessinger A, Kotasek D, Lazarus H, Ljungman P, Maraninchi D, Nabholtz J, Niederwieser D, Ogawa M, Patrone F, Peters W, Rosti G, Rouesse J, Schilcher R, Selby G, Shea T, Shpall E, Spitzer G, Sweet D, Tajima T, Vaughan W, Williams S, Wolff S: Dose intensive therapy in breast cancer. Bone Marrow Transplant 10:67, 1992 (suppl)
41. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, Tepler I, Mazanet R, Lynch C, Pap S, Pelaez J, Reich E, Critchlow J, Demetri G, Bibbo J, Schnipper L, Griffin JD, Frei E, Antman KH: Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 79:3036, 1993
42. Triozzi PL: Autologous bone marrow and peripheral blood progenitor transplant for breast cancer. Lancet 344:418, 1994
43. Somlo G, Doroshow JH, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Akman SA, Ahn C, Sniecinski I: High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 73:125, 1994
44. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132, 1993
45. Ayash LJ, Elias A, Wheeler C, Tepler I, Schwartz G, Schnipper L, Frei E, Antman K: High-dose chemotherapy with autologous stem cell support for breast cancer: A review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. J Hematother 2:507, 1993
46. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO: High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368, 1988
47. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE: High-dose chemotherapy with reinfusion of purged autologous bone marrow as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920, 1991
48. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102, 1992
49. Williams SF, Gilewski T, Mick R, Bitran JC: High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 10:1743, 1992
50. Huber Ch, Niederwieser D, Schönitzer D, Gratwohl A, Buckner D, Margreiter R: Liver transplantation followed by high-dose cyclophosphamide, total body irradiation and autologous bone marrow transplantation for treatment of metastatic breast cancer. A case report. Transplantation 37:311, 1984
51. Niederwieser D, Aulitzky W, Frommhold H, Schönitzer D, Url M, Allerberger F, Wiegele J, Gratwohl A, Braunsteiner H, Huber C: Erfahrungen mit der Knochenmarktransplantation in der Behandlung hämatologischer Neoplasien und solider Tumoren. Wien Klin Wochenschr 2:49, 1987
52. van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethé B, Eynde Bvan den, Uyttenhove C, Renauld J-C, Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:1995
53. Petersen FB, Appelbaum FR, Bigelow CL, Buckner CD, Clift RA, Sanders JE, Storb R, Sullivan KM, Weiden PL, Fefer A: High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced lymphoma. Bone Marrow Transplant 4:483, 1989
54. Martin PJ, Clift RA, Fisher LD, Buckner CD, Hansen JA, Appelbaum FR, Doney K, Sullivan KM, Witherspoon RP, Storb R, Thomas ED: HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: Analysis of survival and remission duration. Blood 72:1978, 1988
55. Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E: A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 8:1239, 1990